There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new vaccines and medicines to address the root cause of disease.
Tony Wood
Chief Scientific Officer-designate
We’re combining the power of genetic and genomic insights into what causes disease, with the speed and scale of artificial intelligence and machine learning (AI/ML) to make better predictions about who a treatment might work for, and why.
We believe this powerful combination of data and technology holds the key to fundamentally transforming medical discovery for the better, improving R&D success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
Our R&D investment in 2024
£6.4bn
An outstanding R&D team of
15k
A Canadian R&D Leader
We are one of the largest research and development (R&D) organizations in Canada. We have invested over $121 million in Canadian research and development (R&D) in 2023.
To accelerate the discovery of new medicines and vaccines, we make collaboration part of our business model. Partnering with academic researchers and public organizations is a key part of our research efforts and we have a range of projects in place to allow us to work with and support new projects that fall within the specific areas of science we are interested in exploring.
In Canada, GSK is actively engaged in the support of research and innovation in the life sciences, and the commercialization of new technologies. GSK Canada works actively with academic researchers, university industry liaison and technology transfer offices, and innovation hubs such as the Quebec Consortium for Drug Development (CQDM) to investigate new therapeutic targets as well as disruptive platforms for discovery and development.
Our pipeline
As a global biopharma company, we invest heavily in our industry-leading pipeline of new products and specialty medicines that help us to get ahead of disease together.
the number of assets in phase III clinical development during last 5 years
Therapeutic areas
The four areas of human health we focus on to get ahead of disease are: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
We remain open to opportunities outside these core areas where the science aligns with our strategic approach.
